I never got the chance to flesh out this blog post to the extent planned, but I thought I would publish it nonetheless to capture the archive of links, statements, etc regarding the controversy around the disclosure of the safety and efficacy data for "FLINT" study evaluating obeticholic acid (OCA) from Intercept Pharma $ICPT in nonalcoholic steatohepatitis (NASH).
Those of us who raised an eyebrow about the initial disclosure from ICPT have been correct in that there was more to the story. Thankfully much more of the full picture is now in the public domain and the path forward will lie in the hands of the upcoming data from the clinical trial. The assessment of management's behavior and the impact on credibility going forward is up to each investor.
Those of us who raised an eyebrow about the initial disclosure from ICPT have been correct in that there was more to the story. Thankfully much more of the full picture is now in the public domain and the path forward will lie in the hands of the upcoming data from the clinical trial. The assessment of management's behavior and the impact on credibility going forward is up to each investor.
RSS Feed
